News | May 22, 2021
Balaxi records Q4 FY21 revenue of Rs. 53 Cr
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Financial support is being provided as a grant from the Government of India
The company is working closely with its six manufacturing partners in India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Subscribe To Our Newsletter & Stay Updated
